Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Rosell, R; Carcereny, E; Gervais, R; Vergnenegre, A; Massuti, B; Felip, E; Palmero, R; Garcia-Gomez, R; Pallares, C; Sanchez, JM; Porta, R; Cobo, M; Garrido, P; Longo, F; Moran, T; Insa, A; De Marinis, F; Corre, R; Bover, I; Illiano, A; Dansin, E; de Castro, J; Milella, M; Reguart, N; Altavilla, G; Jimenez, U; Provencio, M; Moreno, MA; Terrasa, J; Munoz-Langa, J; Valdivia, J; Isla, D; Domine, M; Molinier, O; Mazieres, J; Baize, N; Garcia-Campelo, R; Robinet, G; Rodriguez-Abreu, D; Lopez-Vivanco, G; Gebbia, V; Ferrera-Delgado, L; Bombaron, P; Bernabe, R; Bearz, A; Artal, A; Cortesi, E; Rolfo, C; Sanchez-Ronco, M; Drozdowskyj, A; Queralt, C; de Aguirre, I; Ramirez, JL; Sanchez, JJ; Molina, MA; Taron, M; Paz-Ares, L.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

LANCET ONCOLOGY. 2012; 13(3): 239-246 Nº de citas: 4909 [doi:10.1016/S1470-2045(11)70393-X]

Albanell, J; Gonzalez, A; Ruiz-Borrego, M; Alba, E; Garcia-Saenz, JA; Corominas, JM; Burgues, O; Furio, V; Rojo, A; Palacios, J; Bermejo, B; Martinez-Garcia, M; Limon, ML; Munoz, AS; Martin, M; Tusquets, I; Rojo, F; Colomer, R; Faull, I; Lluch, A.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer

ANNALS OF ONCOLOGY. 2012; 23(3): 625-631 Nº de citas: 104 [doi:10.1093/annonc/mdr278]

Romero, A; Caldes, T; Diaz-Rubio, E; Martin, M.

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

CLINICAL & TRANSLATIONAL ONCOLOGY. 2012; 14(3): 163-168 Nº de citas: 22 [doi:10.1007/s12094-012-0779-1]

Eiermann, W; Bergh, J; Cardoso, F; Conte, P; Crown, J; Curtin, NJ; Gligorov, J; Gusterson, B; Joensuu, H; Linderholm, BK; Martin, M; Penault-Llorca, F; Pestalozzi, BC; Razis, E; Sotiriou, C; Tjulandin, S; Viale, G.

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

BREAST. 2012; 21(1): 20-26 Nº de citas: 24 [doi:10.1016/j.breast.2011.09.006]

Llombart-Cussac, A; Ruiz, A; Anton, A; Barnadas, A; Antolin, S; Ales-Martinez, JE; Alvarez, I; Andres, R; Saenz, JAG; Lao, J; Carrasco, E; Camara, C; Casas, I; Martin, M.

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial

CANCER. 2012; 118(1): 241-247 Nº de citas: 21 [doi:10.1002/cncr.26299]

Marquez-Rodas, I; Lopez-Trabada, D; Blanco, ABR; Cabello, SC; Gomez, MIP; Clemente, MO; Calvo, FA; Martin, M.

Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study

ONCOLOGY. 2012; 82(1): 30-34 Nº de citas: 6 [doi:10.1159/000335960]

Sorensen, SV; Goh, JW; Pan, F; Chen, C; Yardley, D; Martin, M; Knopf, K; Benedict, A; Giorgetti, C; Iyer, S.

INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2012; 28(1): 12-21 Nº de citas: 63 [doi:10.1017/S026646231100064X]

Arija, JAA; Beca, RG; Lopez, CL; Dominguez, PS; Lovelle, AS; Gilarranz, YJ.

Treatment of the patient with castration-resistant biochemical progression of prostate cancer

ARCHIVOS ESPANOLES DE UROLOGIA. 2012; 65(1): 185-192 Nº de citas: 1

Martin, M; Sanchez-Rovira, P; Munoz, M; Baena-Canada, JM; Mel, JR; Margeli, M; Ramos, M; Martinez, E; Garcia-Saenz, JA; Casado, A; Jaen, AM; Gonzalez-Farre, X; Escudero, MJ; Rodriguez-Martin, C; Carrasco, E.

Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study

ANNALS OF ONCOLOGY. 2011; 22(12): 2591-2596 Nº de citas: 28 [doi:10.1093/annonc/mdr024]

Alvarez, RH; Guarneri, V; Icli, F; Johnston, S; Khayat, D; Loibl, S; Martin, M; Zielinski, C; Conte, P; Hortobagyi, GN.

Bevacizumab Treatment for Advanced Breast Cancer

ONCOLOGIST. 2011; 16(12): 1684-1697 Nº de citas: 18 [doi:10.1634/theoncologist.2011-0113]

Marquez-Rodas, I; Algarra, SM; Izquierdo, JAA; Cabello, SC; Martin, M.

A new era in the treatment of melanoma: from biology to clinical practice

CLINICAL & TRANSLATIONAL ONCOLOGY. 2011; 13(11): 787-792 Nº de citas: 9 [doi:10.1007/s12094-011-0734-6]

Martin, M; Romero, A; Cheang, MCU; Garcia-Asenjo, JA; Garcia-Saenz, JA; Oliva, B; Roman, JM; He, X; Casado, A; de la Torre, J; Furio, V; Puente, J; Caldes, T; Vidart, JA; Lopez-Tarruella, S; Diaz-Rubio, E; Perou, CM.

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2011; 128(1): 127-136 Nº de citas: 65 [doi:10.1007/s10549-011-1461-y]

Bourgier, C; Calvo, FA; Marsiglia, H; Martin, M.

Overview of preoperative radiochemotherapy in breast cancer: past or future?

CLINICAL & TRANSLATIONAL ONCOLOGY. 2011; 13(7): 446-450 Nº de citas: 7 [doi:10.1007/s12094-011-0681-2]

Sierra-Filardi, E; Puig-Kroger, A; Blanco, FJ; Nieto, C; Bragado, R; Palomero, I; Bernabeu, C; Vega, MA; Corbi, AL.

Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers

BLOOD. 2011; 117(19): 5092-5101 Nº de citas: 247 [doi:10.1182/blood-2010-09-306993]

Romero, A; Martin, M; Cheang, MCU; Garcia-Asenjo, JAL; Oliva, B; He, XP; de la Hoya, M; Saenz, JAG; Fernandez, MA; Rubio, ED; Perou, CM; Llopis, TC.

Assessment of Topoisomerase II alpha Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization

AM J PATHOL. 2011; 178(4): 1453-1460 Nº de citas: 73 [doi:10.1016/j.ajpath.2010.12.042]

Caronia, D; Martin, M; Sastre, J; de la Torre, J; Garcia-Saenz, JA; Alonso, MR; Moreno, LT; Pita, G; Diaz-Rubio, E; Benitez, J; Gonzalez-Neira, A.

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

CLINICAL CANCER RESEARCH. 2011; 17(7): 2006-2013 Nº de citas: 78 [doi:10.1158/1078-0432.CCR-10-1741]

Martin, M; Roche, H; Pinter, T; Crown, J; Kennedy, MJ; Provencher, L; Priou, F; Eiermann, W; Adrover, E; Lang, I; Ramos, M; Latreille, J; Jagiello-Gruszfeld, A; Pienkowski, T; Alba, E; Snyder, R; Almel, S; Rolski, J; Munoz, M; Moroose, R; Hurvitz, S; Banos, A; Adewoye, H; Hei, YJ; Lindsay, MA; Rupin, M; Cabaribere, D; Lemmerick, Y; Mackey, JR.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

LANCET ONCOLOGY. 2011; 12(4): 369-376 Nº de citas: 76 [doi:10.1016/S1470-2045(11)70037-7]

Valero, V; Forbes, J; Pegram, MD; Pienkowski, T; Eiermann, W; von Minckwitz, G; Roche, H; Martin, M; Crown, J; Mackey, JR; Fumoleau, P; Rolski, J; Mrsic-Krmpotic, Z; Jagiello-Gruszfeld, A; Riva, A; Buyse, M; Taupin, H; Sauter, G; Press, MF; Slamon, DJ.

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

JOURNAL OF CLINICAL ONCOLOGY. 2011; 29(2): 149-156 Nº de citas: 198 [doi:10.1200/JCO.2010.28.6450]